Clinical trials: COVID19 ARDS
Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe)
Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)
This is a multi-center, randomized, placebo controlled, interventional phase 2A trial to evaluate the safety profile and potential efficacy of multi-dosing of mesenchymal stromal cells (MSC) for patients with SARS-CoV-2…
- Conditions
- Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe), COVID-19 Pneumonia
- Trial name
- NCT04466098
- Testing
- Mesenchymal stromal cells
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Pneumonia, Viral
Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia
Severe Acute Respiratory Syndrome (SARS) SARS-CoV-2, name of the Coronavirus Group of international Committee on taxonomy of viruses, is an emerging virus from the family of coronaviridae, responsible for the COVID-19 pandemic.
- Trial name
- PULCO-19 (NCT04422613)
- Testing
- pulmonary anomalies 4 months after documented COVID-19 pneumonia
- Where
- France
- Volunteers
- 73 people
- Sponsor
- University Hospital, Toulouse
Covid19, Post Traumatic Stress Disorder
Quality of Life After COVID-19 Related Acute respIratory Distress Syndrome Among ICU Survivors Patients in Italy: the ODISSEA Study.
Acute respiratory insufficiency is one of the principal causes of intensive care admission for COVID 19 positive patients. This may determine a variable mortality rate ranging from 25-30%.
- Conditions
- Covid19, Post Traumatic Stress Disorder, Quality of Life
- Trial name
- ODISSEA (NCT04860687)
- Where
- 8 sites in Italy
- Volunteers
- 309 people
- Sponsor
- Azienda Sanitaria-Universitaria Integrata di Udine
ARDS, Human, COVID
Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency
SARS-CoV-2, one of a family of human coronaviruses, was initially identified in December 2019 in Wuhan city. This new coronavirus causes a disease that has now been named COVID-19.
- Trial name
- COVIPOC (NCT04594668)
- Testing
- Senicapoc
- Where
- 4 sites in Denmark
- Volunteers
- 46 people
- Sponsor
- University of Aarhus
COVID-19, Organ Dysfunction Syndrome Sepsis
Mechanisms for Organ Dysfunction in Covid-19
The study aims to investigate organ dysfunction and biomarkers in patients with suspected or verified COVID-19 during intensive care at Uppsala University Hospital.
- Conditions
- COVID-19, Organ Dysfunction Syndrome Sepsis, Organ Dysfunction Syndrome, Multiple, Septic Shock
- Trial name
- UMODCOVID19 (NCT04316884)
- Where
- Sweden
- Volunteers
- 380 people
- Sponsor
- Uppsala University
Lung Injury, ARDS
Point-of-care Lung Ultrasound (POCUS)-Integrated Study of Admitted Patients With COVID-19
This study seeks to define the ultrasound profile of patients with COVID-19, and document the progression of these ultrasound findings to develop prognostication and clinical decision instruments that can help guide management of…
- Conditions
- Lung Injury, ARDS, Acute Cardiac Event, Covid19
- Trial name
- PIOS-COVID (NCT05228717)
- Testing
- Point of Care Ultrasound
- Where
- 4 sites in United States
- Volunteers
- 240 people
- Sponsor
- Olive View-UCLA Education & Research Institute
ARDS, Human, COVID-19
Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID)
Experimental intervention: Insertion of Extracorporal Membrane Oxygenation (ECMO) within 24 hours of referral to an Intensive Care Unit.
- Trial name
- ECMO-VID (NCT04341285)
- Testing
- ECMO Implantation
- Where
- Germany
- Sponsor
- University Hospital Tuebingen
ARDS, COVID-19
ECMO for COVID-19 vs Influenza A H1N1 Associated ARDS
Objective: Veno-venous ECMO has been used as a rescue therapy for patients with severe ARDS associated to influenza A H1N1 and COVID19 viral pneumonia.
- Conditions
- ARDS, COVID-19, H1N1 Influenza
- Trial name
- InfluCOV_ECMO (NCT05080933)
- Where
- Italy
- Volunteers
- 308 people
- Sponsor
- University of Turin, Italy
Coronavirus Infection, Acute Respiratory Distress Syndrome
Pilot Study on Cytokine Filtration in COVID-19 ARDS
Background: There are no proven therapies for COVID-19 infection. COVID-19 infects the respiratory epithelium of the lower airways, causing widespread damage via cytopathic effects, resulting in severe inflammation and…
- Conditions
- Coronavirus Infection, Acute Respiratory Distress Syndrome, COVID
- Trial name
- CytokCOVID19 (NCT04361526)
- Testing
- Cytokine Adsorption
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Manuel Castellà
Respiratory Infection, Pneumonia
Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia
The main objectives of the trial are to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult hospitalized subjects with non-severe community-acquired…
- Conditions
- Respiratory Infection, Pneumonia, Community-acquired Pneumonia, Acute Respiratory Distress Syndrome
- Trial name
- TRICOVID (NCT05531149)
- Testing
- Trimodulin
- Where
- 64 sites in Argentina, Austria and 12 more
- Volunteers
- 107 people
- Sponsor
- Biotest
ARDS, Covid19
Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS
This is a randomized, double-blinded, placebo-controlled study of AVM0703 administered as a single intravenous (IV) infusion to patients with moderate or severe immediately life-threatening Acute Respiratory Distress Syndrome…
- Conditions
- ARDS, Covid19, Influenza, Human
- Trial name
- AVM0703 (NCT04366115)
- Testing
- AVM0703
- Volunteers
- 16 people
- Sponsor
- AVM Biotechnology Inc
Covid19, Influenza
Wide Scale Monitoring for Acute Respiratory Infection Using a Mobile-Based Study Platform
This is a prospective observational study using a mobile study platform (app) that is designed for use on Android phones. Study participants will provide baseline demographic and medical information and report symptoms of…
- Conditions
- Covid19, Influenza, Respiratory Tract Infections, Acute Respiratory Tract Infection
- Trial name
- NCT04663776
- Where
- United States
- Volunteers
- 16,000 people, healthy volunteers welcome
- Sponsor
- Boston Children's Hospital
COVID, Corona Virus Infection
Intensive Care Associated Complications and Outcome of Acute Respiratory Distress Syndrome Due to COVID-19
COVID-19 patients with a severely symptomatic progression with development of an Acute respiratory distress syndrome (ARDS) due to SARS-CoV-2 need prolonged intensive care treatment involving pharmacological immobilization…
- Conditions
- COVID, Corona Virus Infection, Sars-CoV2
- Trial name
- NCT04397172
- Testing
- Study Arm
- Where
- Switzerland
- Volunteers
- 48 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
ARDS, COVID-19 Acute Respiratory Distress Syndrome
Comparison of ARDS COVID-19 (WHO) vs ARDS Influenza in the ICU
Since the beginning of the SARS CoV 2 pandemia, the SARS CoV 2 was frequently compared with the seasonal influenza virus. However, few studies compared patients presenting acute respiratory distress syndrome (ARDS) induced by…
- Conditions
- ARDS, COVID-19 Acute Respiratory Distress Syndrome, Influenza
- Trial name
- NCT04941092
- Testing
- no intervention
- Where
- France
- Volunteers
- 157 people
- Sponsor
- Central Hospital, Nancy, France
Acute Respiratory Distress Syndrome, Inflammation
Dexmedetomidine to Improve Outcomes of ARDS in Critical Care COVID-19 Patients
A continuous infusion of Dexmedetomidine (DEX) will be administered to 80 patients admitted to Critical Care because of signs of Respiratory Insufficiency requiring non-invasive ventilation.
- Conditions
- Acute Respiratory Distress Syndrome, Inflammation, Dexmedetomidine, Cytokine Storm
- Trial name
- COVID-DEX (NCT04358627)
- Testing
- Dexmedetomidine Injectable Product
- Volunteers
- 80 people
- Sponsor
- Hospital Clinic of Barcelona
Acute Respiratory Distress Syndrome Caused by COVID-19
Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19
Background: There are no proven therapies specific for Covid-19. The full spectrum of Covid-19 ranges from asymptomatic disease to mild respiratory tract illness to severe pneumonia, acute respiratory distress syndrome (ARDS)…
- Trial name
- DEXA-COVID19 (NCT04325061)
- Testing
- Dexamethasone
- Where
- 24 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Hospital Universitario de Gran Canaria Doctor Negrín
COVID-19, Acute Respiratory Distress Syndrome Due to COVID-19
Post-intensive Care Syndromes in Pregnant Patients With Respiratory Failure and COVID-19 Compared to Non-pregnant Patients With Respiratory Failure and COVID-19
The aim of this study is to characterize patients in the Post-Intensive-Care-Syndrome (PICS) outpatient clinic based on routine data and to evaluate their treatment outcome over the course of their treatment.
- Conditions
- COVID-19, Acute Respiratory Distress Syndrome Due to COVID-19, Pregnancy Related
- Trial name
- NCT07051967
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Charite University, Berlin, Germany
Prone Position, Severe Acute Respiratory Syndrome Coronavirus 2
Evaluation of Sedation in COVID-19 ARDS
This study focuses on the evaluation of various factors repeatedly discussed in relation to the impaired sedation of intubated ventilated COVID-19 patients.
- Conditions
- Prone Position, Severe Acute Respiratory Syndrome Coronavirus 2, Hypnotics and Sedatives, Pulmonary Ventilation
- Trial name
- NCT04667936
- Testing
- Treatment group
- Where
- Germany
- Volunteers
- 114 people
- Sponsor
- Goethe University
COVID-19
In Situ Thrombolysis With tPA and Inflow Perfusion Analysis in Patient With Severe Covid-19 Infection
To estimate the pulmonary response microvascular thrombosis in critical patients due to SARS-Cov-2., at the Hospital General de México "Dr.
- Trial name
- NCT04926428
- Testing
- tPA
- Where
- Mexico
- Volunteers
- 15 people
- Sponsor
- Grupo Mexicano para el Estudio de la Medicina Intensiva
Covid-19, ARDS
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study
Several treatments have been used in during the Covid-19 pandemic of 2020. Using patients' registries from several hospitals in Paris, the investigators retrospectively analyzed associations between specific treatments, including…
- Conditions
- Covid-19, ARDS, Pneumonia
- Trial name
- NCT04365764
- Where
- 2 sites in France
- Volunteers
- 400 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere